Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.25	$0.07 ▼ $5.48	$2.92M	2.07	4.87 million shs	22.99 million shs
CARM Carisma Therapeutics	$0.28 -4.5%	$0.40	$0.14 ▼ $1.27	$11.66M	1.79	5.89 million shs	395,854 shs
CSCI COSCIENS Biopharma	$2.89 +1.4%	$3.64	$1.96 ▼ $6.40	$9.10M	0.91	12,912 shs	7,096 shs
IMCC IM Cannabis	$2.58 -3.0%	$2.84	$1.29 ▼ $7.12	$13.55M	2.2	117,370 shs	46,043 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	-95.44%
CARM Carisma Therapeutics	0.00%	+8.15%	-25.55%	+53.52%	-73.93%
CSCI COSCIENS Biopharma	0.00%	-17.74%	-32.10%	-15.49%	+293,999,900.00%
IMCC IM Cannabis	0.00%	-2.92%	-22.22%	+72.27%	-13.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	1.867 of 5 stars	3.0	0.0	0.0	4.3	0.0	0.0	1.3
CARM Carisma Therapeutics	3.1691 of 5 stars	3.4	5.0	0.0	0.0	3.3	0.8	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	0.9317 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	589.96% Upside
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
IMCC IM Cannabis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AFMD, CSCI, CARM, and IMCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
CARM Carisma Therapeutics	$19.63M	0.59	N/A	N/A	($0.67) per share	-0.42
CSCI COSCIENS Biopharma	$9.03M	1.01	N/A	N/A	$3.49 per share	0.83
IMCC IM Cannabis	$39.44M	0.34	N/A	N/A	$1.03 per share	2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-211.28%	11/5/2025 (Estimated)
CSCI COSCIENS Biopharma	-$15.31M	-$6.01	N/A	∞	N/A	-199.55%	-130.49%	-51.40%	N/A
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-59.80%	-5.15%	N/A

Latest AFMD, CSCI, CARM, and IMCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CSCI COSCIENS Biopharma	N/A	-$0.85	N/A	-$0.85	N/A	$2.75 million
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
CARM Carisma Therapeutics	N/A	0.48	0.48
CSCI COSCIENS Biopharma	N/A	2.88	2.54
IMCC IM Cannabis	0.32	0.72	0.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
CARM Carisma Therapeutics	44.27%
CSCI COSCIENS Biopharma	0.73%
IMCC IM Cannabis	7.68%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
CARM Carisma Therapeutics	6.90%
CSCI COSCIENS Biopharma	0.10%
IMCC IM Cannabis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
CSCI COSCIENS Biopharma	20	3.15 million	3.14 million	N/A
IMCC IM Cannabis	340	5.25 million	N/A	Not Optionable

AFMD, CSCI, CARM, and IMCC Headlines

Recent News About These Companies

IM Cannabis (NASDAQ:IMCC) Rating Lowered to Hold at Wall Street Zen

August 18 at 3:37 AM | americanbankingnews.com

IM Cannabis files to sell 4.98M common shares for holders

August 14, 2025 | msn.com

IM Cannabis Announces Warrant Amendments and Resale Registration Filing

August 14, 2025 | msn.com

IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

August 13, 2025 | prnewswire.com

IM Cannabis Reports Second Quarter 2025 Financial Results

August 12, 2025 | prnewswire.com

IM Cannabis to Report Second Quarter 2025 Financial Results on Tuesday, August 12th at 9:00am ET

August 4, 2025 | prnewswire.com

IM Cannabis Closes Private Placement for Gross Proceeds of Approximately US$4.1 Million

July 31, 2025 | prnewswire.com

IM CANNABIS ANNOUNCES FILING OF SHELF REGISTRATION STATEMENT ON FORM F-3

July 11, 2025 | prnewswire.com

IM Cannabis Announces the Signing of a Loan Agreement and Appointment of Oz Adler to Board of Directors

July 9, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

July 1, 2025 | prnewswire.com

IM Cannabis (NASDAQ:IMCC) Stock, Earnings Estimates, EPS, And Revenue

June 1, 2025 | benzinga.com

IM Cannabis Stock Price, Quotes and Forecasts | NASDAQ:IMCC | Benzinga

June 1, 2025 | benzinga.com

CSE Bulletin: Delist - IM Cannabis Corp. (IMCC)

May 28, 2025 | newsfilecorp.comN

IM Cannabis Corp.: IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | finanznachrichten.de

IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities Exchange

May 28, 2025 | prnewswire.com

IM Cannabis Provides Corporate Updates

May 27, 2025 | prnewswire.com

IM Cannabis Corp. (IMCC) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

IM Cannabis Reports First Quarter Financial Results

May 15, 2025 | prnewswire.com

IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

May 7, 2025 | prnewswire.com

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

May 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AFMD, CSCI, CARM, and IMCC Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Carisma Therapeutics NASDAQ:CARM

$0.28 -0.01 (-4.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 -0.01 (-2.15%)

As of 05:22 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

COSCIENS Biopharma NASDAQ:CSCI

$2.89 +0.04 (+1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 -0.01 (-0.35%)

As of 04:10 PM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

IM Cannabis NASDAQ:IMCC

$2.58 -0.08 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 0.00 (-0.19%)

As of 04:07 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time